Pages that link to "Q48859235"

The following pages link to Non-competitive N-methyl-D-aspartate antagonists are potent activators of ventral tegmental A10 dopamine neurons (Q48859235):

Displaying 50 items.

• Sigma receptor agonists provide neuroprotection in vitro by preserving bcl-2 (Q24649613) (← links)
• Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents (Q30406145) (← links)
• Localization of brain reinforcement mechanisms: intracranial self-administration and intracranial place-conditioning studies (Q33662343) (← links)
• Current hypotheses on sigma receptors and their physiological role: possible implications in psychiatry (Q33921280) (← links)
• The selective vulnerability of striatopallidal neurons (Q33939097) (← links)
• Pharmacology and behavioral pharmacology of the mesocortical dopamine system (Q34104228) (← links)
• Rewarding actions of phencyclidine and related drugs in nucleus accumbens shell and frontal cortex (Q34378202) (← links)
• Differential effects of agents acting at various sites of the NMDA receptor complex in a place preference conditioning model (Q34413503) (← links)
• Restoring mood balance in depression: ketamine reverses deficit in dopamine-dependent synaptic plasticity (Q34466181) (← links)
• Sigma(1) (sigma(1)) receptor antagonists represent a new strategy against cocaine addiction and toxicity (Q34804462) (← links)
• The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment (Q35071686) (← links)
• Impact of subanesthetic doses of ketamine on AMPA-mediated responses in rats: An in vivo electrophysiological study on monoaminergic and glutamatergic neurons (Q35748576) (← links)
• Selective reduction of N-methyl-D-aspartate-evoked responses by 1,3-di(2-tolyl)guanidine in mouse and rat cultured hippocampal pyramidal neurones (Q36329691) (← links)
• Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway (Q36877274) (← links)
• Intracerebroventricular administration of NMDA-R1 antisense oligodeoxynucleotide significantly alters the activity of ventral tegmental area dopamine neurons: an electrophysiological study (Q38301802) (← links)
• The Rapidly Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits (Q39758341) (← links)
• Antagonists of the NMDA receptor-channel complex and motor coordination (Q40464594) (← links)
• Behavioural pharmacology of glutamate receptors in the basal ganglia (Q41509236) (← links)
• Modulation of dopamine neuronal activity by glutamate receptor subtypes (Q41509305) (← links)
• DTG-induced circling behaviour in rats may involve the interaction between σ sites and nigro-striatal dopaminergic pathways (Q41678370) (← links)
• The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants (Q41749963) (← links)
• Jun, Fos and Krox in the hippocampus after noxious stimulation: simultaneous-input-dependent expression and nuclear speckling (Q42501222) (← links)
• Delayed onset of enhanced MK-801-induced motor hyperactivity after neonatal lesions of the rat ventral hippocampus (Q43546710) (← links)
• Involvement of dopaminergic system in the nucleus accumbens in the discriminative stimulus effects of phencyclidine (Q43996572) (← links)
• MK-801- and ethanol-induced activity in inbred long-sleep and short-sleep mice: dopamine and serotonin systems (Q44237449) (← links)
• Long-term potentiation in visual cortical projections to the medial prefrontal cortex of the rat. (Q44505611) (← links)
• Ketamine induces dopamine-dependent depression of evoked hippocampal activity in the nucleus accumbens in freely moving rats. (Q45221831) (← links)
• The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders (Q46296210) (← links)
• The absence of 5-HT(1A) receptors has minor effects on dopamine but not serotonin release evoked by MK-801 in mice prefrontal cortex. (Q46506812) (← links)
• Effects of ketamine on the unconditioned and conditioned locomotor activity of preadolescent and adolescent rats: impact of age, sex, and drug dose (Q46764650) (← links)
• The ketamine-like compound methoxetamine substitutes for ketamine in the self-administration paradigm and enhances mesolimbic dopaminergic transmission. (Q47448107) (← links)
• Examination of clozapine and haloperidol in improving ketamine-induced deficits in an incremental repeated acquisition procedure in BALB/c mice (Q47633556) (← links)
• NMDA receptors mediate lasting increases in anxiety-like behavior produced by the stress of predator exposure--implications for anxiety associated with posttraumatic stress disorder (Q48266174) (← links)
• Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation. (Q48351969) (← links)
• Phencyclidine-induced potentiation of brain stimulation reward: acute effects are not altered by repeated administration (Q48389619) (← links)
• Effects of phencyclidine on spontaneous and excitatory amino acid-induced activity of ventral tegmental dopamine neurons: An extracellular in vitro study (Q48391236) (← links)
• Sigma 1 receptor subtype is involved in the facilitation of cortical dopaminergic transmission in the rat brain (Q48633780) (← links)
• Effects of competitive N-methyl-d-aspartate antagonists on midbrain dopamine neurons: An electrophysiological and behavioral comparison to phencyclidine (Q48644685) (← links)
• Effects of ketamine on dopamine metabolism during anesthesia in discrete brain regions in mice: comparison with the effects during the recovery and subanesthetic phases (Q48655663) (← links)
• Effects of post-ethanol administration of NMDA and non-NMDA receptor antagonists on the development of ethanol tolerance in C57B1 mice (Q48813495) (← links)
• MK-801 increases locomotor activity without elevating extracellular dopamine levels in the nucleus accumbens (Q48906983) (← links)
• The impact of a competitive and a non-competitive NMDA receptor antagonist on dopaminergic neurotransmission in the rat ventral tegmental area and substantia nigra (Q49028706) (← links)
• The delayed effects of DTG and MK-801 on latent inhibition in a conditioned taste-aversion paradigm (Q50134834) (← links)
• Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia (Q51375205) (← links)
• The dopamine antagonist sch 23390 reverses dizocilpine-induced blockade of cocaine sensitization (Q51396429) (← links)
• Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine (Q51436028) (← links)
• Similar ameliorating effects of benzomorphans and 5-HT2 antagonists on drug-induced impairment of passive avoidance response in mice: comparison with acetylcholinesterase inhibitors (Q52068537) (← links)
• Rewarding effects elicited by the microinjection of either AMPA or NMDA glutamatergic antagonists into the ventral tegmental area revealed by an intracranial self-administration paradigm in mice. (Q52184216) (← links)
• Development of both conditioning and sensitization of the behavioral activating effects of amphetamine is blocked by the non-competitive NMDA receptor antagonist, MK-801. (Q52228738) (← links)
• The effects of haloperidol and clozapine on the disruption of sensorimotor gating induced by the noncompetitive glutamate antagonist MK-801. (Q52511472) (← links)